The Therapeutic Peptide Production Ecosystem Pharmaceutical Companies, Compounders, Contract Manufacturers, and Alternative Supply Channels

Imagine three containers that claim the same peptide. The first is an approved finished medicine: a pen or carton whose manufacturer, lot, labelled indication and pharmacovigilance home can be named. The second is a compounded preparation dispensed after a telehealth questionnaire, mixed in a pharmacy that may be a traditional compounder or an outsourcing facility, priced for cash and advertised beside spa services. The third is a “research chemical” sold with a PDF certificate of analysis and a sentence that says it is not for human use. To a casual eye they are the same molecule. To inspectors, insurers and forensic chemists they are different objects.^{7, 18}

This monograph is about those objects — and about the ecosystem that produces them. It is a map of workshops, not a menu of treatments. General Peptide Monograph 09 asked how peptide medicines are synthesised and verified. General Peptide Monograph 11 asked what legal “passports” products carry into the marketplace. This fourteenth monograph asks a prior, blunter question: who is permitted to make what, under which quality system, and why those differences matter when demand outruns licensed supply.

Primary jurisdiction for the structural account is the United States: the Food and Drug Administration (FDA), the Federal Food, Drug, and Cosmetic Act (FD&C Act), the Public Health Service Act for many biologics, and the Drug Quality and Security Act (DQSA) framework that created modern federal compounding categories after the 2012 New England Compounding Center disaster. Other regulators — EMA, MHRA, Health Canada, TGA, PMDA, NMPA, CDSCO, MFDS, ANVISA, WHO — appear as labelled comparisons. Time-sensitive claims carry an effective or access date. Binding statute is distinguished from regulation, guidance, draft guidance, enforcement discretion and industry practice.

Section 02The workshop test

Sequence identity is a poor passport. Manufacturing route — recombinant expression, solid-phase synthesis, hybrid lipidation — can change impurity profiles even when the amino-acid string matches. Follow-on and compounded GLP-1 products have been shown, in analytical programmes discussed in the peer-reviewed literature, to differ from originators in impurity composition, stability behaviour and potential immunogenicity risk; those differences are not settled by a seller’s claim that “the sequence is the same.”¹⁷ A certificate of analysis answers a narrow laboratory question on a named sample. It does not recreate a validated commercial quality system, a labelled indication, or a pharmacovigilance obligation.

The practical distinctions that prevent expensive mistakes are few and stubborn:

Online commerce collapses these categories in public. Clinics advertise compounded incretin analogues beside the word “FDA” in ways that imply approval the preparation does not have. Research sellers print human-use disclaimers beside dosing calculators. Counterfeit pens appear inside legitimate wholesale networks — including, in WHO’s June 2024 medical-product alert, falsified Ozempic (semaglutide) batches detected in Brazil, the United Kingdom and the United States after entering regulated distribution. The rest of this monograph explains how the workshops differ, how they interact, and what happens when demand, price and shortage rewrite the map.^{7, 12, 18}

A second collapse is temporal. A workshop that was lawfully busy during an FDA shortage listing may become noncompliant days after the listing clears, even if the same patients, clinics and cash-pay menus remain. A Federal Register proposal can dominate industry commentary months before it becomes a final determination — or fails to. This rewrite therefore dates shortage resolutions, enforcement-discretion windows, the May–July 2026 503B Bulks List proposal for major GLP-1 agonists, and WHO falsification alerts as as-of facts through 5 August 2026, and refuses to narrate proposals as if they were already law.

Therapeutic peptides did not invent drug regulation; they inherited it. The United States story that still structures global expectations begins with the Pure Food and Drug Act of 1906, which attacked misbranding and adulteration more than it demanded proof of benefit. The Federal Food, Drug, and Cosmetic Act of 1938 answered the sulfanilamide elixir disaster with a safety standard for new drugs. The Kefauver–Harris Amendments of 1962, after thalidomide, added efficacy and transformed the modern new-drug application. Biologics carried a parallel lineage under the Public Health Service Act. None of these statutes named “semaglutide” or “solid-phase peptide synthesis.” They named obligations that later peptide products would have to meet.

Industrial peptide manufacture grew inside that frame. Recombinant expression made insulin and later growth hormone into scalable biologics; chemical synthesis and hybrid processes made incretin analogues and other engineered peptides into commercial products whose impurity profiles depend on process history, not only on the primary sequence.^{16, 17} Generic and biosimilar pathways — Hatch–Waxman for many small-molecule drugs, the BPCIA for biologics, and jurisdiction-specific routes for synthetic peptide follow-ons — were invented to create competition without inventing a second originator from scratch. Insulin biosimilars and analogues illustrate both the promise and the friction of follow-on entry across markets.^{9, 10, 15}

Section 04The compounding fracture: NECC and DQSA

Pharmacy compounding is older than the FDA. What is modern is the federal attempt to distinguish a neighbourhood craft from a stealth manufacturer. In 2012, contaminated methylprednisolone acetate produced by the New England Compounding Center caused a multistate fungal meningitis outbreak. Contemporaneous CDC tallies and later summaries place the human cost in the range of roughly seven hundred fifty illnesses and more than sixty deaths across about twenty states — figures that vary slightly by reporting date, but not in moral scale. The outbreak made the craft-versus-manufacturer distinction lethal rather than academic. Congress answered on 27 November 2013 with the Drug Quality and Security Act. Title I clarified traditional compounding under section 503A and created section 503B outsourcing facilities: entities that may compound sterile drugs in batches, register with FDA, and accept current good manufacturing practice (CGMP) obligations without obtaining product-by-product premarket approval.

That compromise still defines the United States peptide compounding fight. A 503A pharmacy is supposed to fill a patient-specific prescription under state board oversight, with United States Pharmacopeia chapters such as <795>, <797> and <800> often incorporated through state law as professional standards rather than free-standing federal statutes. A 503B facility may produce office stock under federal registration and CGMP, but its bulk-drug substance options are cabined by the 503B Bulks List and by the drug-shortage list. FDA’s own information page is blunt: drugs compounded by an outsourcing facility can qualify for exemptions from approval requirements and from the requirement to label with adequate directions for use, but not from CGMP; facilities are inspected on a risk-based schedule and must report adverse events and product information. Registration is annual, fee-bearing, and electronic unless waived. Neither pathway is an NDA. Neither pathway makes a compounded vial “generic” in the Hatch–Waxman sense.⁷

Two quality languages now sit beside each other and are often confused in public. USP chapters <795>, <797> and <800> are professional standards that state boards commonly adopt for traditional pharmacy compounding; they are not, by themselves, the federal CGMP framework that applies to registered outsourcing facilities and conventional drug manufacturers. CGMP, as FDA explains for 503B facilities, is the manufacturing quality system that survives even when product-approval and adequate-directions labelling exemptions apply. A clinic advertisement that says “503B” or “USP” as if those phrases were synonyms for “FDA-approved medicine” is performing a category error. The sterile-injectable physics is shared; the accountability stack is not.

Title II of the DQSA — the Drug Supply Chain Security Act — built a parallel reform for the licensed finished-drug chain: serialisation, verification and traceability expectations that, when fully implemented, make diversion and falsification harder inside that chain. Peptide pens and cartons that travel as approved finished drugs inherit that architecture. Compounded preparations, RUO parcels and street-market vials do not automatically inherit it. The falsification cases that matter most for public literacy are therefore of two kinds: products that never entered the licensed chain, and products that impersonated licensed goods well enough to move inside it.

Section 05Shortages rewrite the map

Drug shortages are status-changing events. FDA’s compounding-and-shortages page states the structural rule plainly: when an FDA-approved drug appears on the agency’s drug shortages list, some federal restrictions — including limits on compounding drugs that are essentially copies of approved drugs — may not apply, for compounders that otherwise meet the conditions of section 503A or 503B. Other conditions remain. Compounders may still lack the equipment or expertise to make a particular product, or may decline for business reasons. FDA continues to recommend prescribing an approved drug when one is available and appropriate. When the listing ends, the copy window narrows again. For the GLP-1 class, public chronologies place tirzepatide’s shortage resolution around December 2024 and semaglutide’s around 21 February 2025. Phased enforcement-discretion windows and litigation by the Outsourcing Facilities Association against FDA complicated the operational calendar; secondary legal summaries disagree on exact wind-down days. Those dates are administrative facts about a list and about agency posture, not moral permissions. Residual cash-pay demand, telehealth funnels and clinic advertising do not disappear because a spreadsheet cell changes.^{7, 13, 14}

In May 2026 FDA went further on the 503B side. In Federal Register notice 91 FR 23431 (1 May 2026; document 2026-08552; Docket FDA-2018-N-3240), the agency identified three nominated bulk substances — semaglutide, tirzepatide and liraglutide — and proposed not to include them on the list of bulk drug substances for which there is a clinical need for outsourcing facilities (the 503B Bulks List). On 26 June 2026, 91 FR 38719 extended the comment period to 30 July 2026. As of the research cutoff for this monograph (5 August 2026), that proposal remains a proposal: not a final exclusion, not a statute rewrite, and not a licence for 503A pharmacies to ignore their own copy and prescription conditions. Industry commentary that treats the May notice as a completed ban is premature; industry commentary that treats the July comment close as irrelevant is also premature. Controversies that remain disputed are labelled as disputed below.

Track-and-trace under the Drug Supply Chain Security Act (DSCSA) was meant to harden the approved supply chain against diversion and falsification. It does not convert a research website into a pharmacy, and it does not make a compounded vial interchangeable with a branded pen. WHO’s 2024 falsified-Ozempic alert — products detected inside regulated chains in three countries — shows why that hardening matters and why it is incomplete. The next parts describe the industrial workshops that produce authorised peptides, then the compounding and alternative channels that grew in the gaps.^{4, 18}

An originator pharmaceutical company owns more than a sequence. It owns a product-specific authorisation — typically an NDA or BLA in the United States, a marketing authorisation elsewhere — tied to a validated manufacturing process, labelled claims, pharmacovigilance duties, supply commitments and lifecycle management. Patents and regulatory exclusivities are clocks that shape when competition may enter; they are not certificates that the science is finished. Direct manufacture and outsourced manufacture can coexist inside one licence. What does not coexist is a free pass for a third party to print the brand name on a different process history.

For peptides, that process history is unusually consequential. Semaglutide’s commercial manufacture has been described as a hybrid of recombinant expression and chemical modification; fully synthetic follow-ons assemble the chain by solid-phase methods and attach lipid motifs chemically. Analytical programmes comparing originator and follow-on GLP-1 polypeptides have reported differences in impurity profiles, aggregation behaviour and potential immunogenicity signals even when the intended sequence matches.¹⁷ Those findings do not, by themselves, prove clinical inferiority of every follow-on. They do refute the folk theory that HPLC purity on a seller’s CoA is the whole of pharmaceutical quality.

Section 07Generics, biosimilars and follow-on peptides

Follow-on pathways differ by chemistry and by jurisdiction. Chemically synthesised peptides below certain length thresholds may be treated in the United States more like small-molecule drugs and, in limited cases, pursued through ANDA or 505(b)(2) routes with demanding analytical sameness showings. FDA’s May 2021 final guidance on ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant-DNA origin was written precisely for that seam: to say when a synthetic follow-on may ride an abbreviated pathway against an rDNA-origin reference listed drug, and what impurity and sameness showings the agency expects. Product-specific guidances continue to issue for individual peptide injections; they are agency thinking, not statute, and they do not convert a compounded vial into an ANDA product. Products rooted in recombinant manufacture may face biosimilar or hybrid expectations. Europe distinguishes biosimilar biologics from synthetic follow-on polypeptides that cannot simply borrow the biosimilar pathway. India’s CDSCO has been described as more process-centric and risk-based, sometimes applying biologics-like scrutiny regardless of peptide length.¹⁷

Insulin remains the longest-running public laboratory for peptide follow-ons. Cross-country surveys of long-acting insulin analogues and biosimilars show wide variation in availability, pricing and interchangeability rules; state substitution laws in the United States further mediate whether an interchangeable biosimilar actually displaces the reference product at the counter.^{2, 6, 10, 11} Growth-hormone biosimilars taught a similar lesson earlier: analytical similarity is necessary and not sufficient without a regulatory pathway that the public can understand.^{9, 15}

Section 08CDMOs, API plants and fill-finish

Most peptide programmes do not live entirely inside one corporate campus. Contract development and manufacturing organisations (CDMOs) develop processes, scale synthesis, run analytical methods, and often manufacture API under confidentiality and quality agreements. Separate or integrated sterile fill-finish providers place the drug product into vials, syringes or devices. Technology transfer is a formal risk event: equipment, raw materials, host cells and operators all change impurity and contamination risk. Capacity reservation and long-term supply agreements became strategic assets when incretin demand collided with limited large-scale solid-phase and lyophilisation capacity — a commercial fact reported widely in trade sources and treated here as context, not as a precise market-size truth.

Downstream processing of recombinant insulin illustrates how much of peptide quality lives after the fermenter: capture, purification, folding, and formulation steps determine what patients eventually receive.¹⁶ Visible particulate investigations in therapeutic proteins remind auditors that even licensed biologics manufacturing is a continuous fight against physical contamination modes.⁵ Quality agreements allocate responsibility between sponsor and contractor; they do not dissolve FDA’s view that the licence holder remains accountable for the product that reaches the patient.

Fill-finish is where many peptide programmes become fragile. A drug substance that cleared identity, purity and potency assays can still fail patients if aseptic filling, lyophilisation, stoppering, device assembly or cold-chain labelling is weak. Trade reporting that celebrates new vial and lyophilised drug-product suites at named CDMO sites is therefore not decorative: it marks the bottleneck that shortage politics later converted into compounding politics. The same bottleneck explains why office-stock 503B production and cash-pay clinic menus became economically attractive — they promised presentation formats and local availability that the licensed pen supply could not always match on schedule.

Section 09Testing laboratories, wholesalers, specialty pharmacies

Independent testing laboratories sit beside the industrial map as both safeguard and temptation. Legitimate sponsors qualify labs, validate methods and retain samples. Online sellers purchase a CoA and treat it as a halo. Wholesalers and specialty pharmacies move approved products under DSCSA expectations, cold-chain rules and payer formulary logic. Hospital pharmacies bridge inpatient need, sometimes purchasing from 503B facilities for office stock when a licensed product presentation is unavailable. Each of these actors can be compliant or noncompliant; the category name is not a virtue badge.

Internationally, the rhyme is clearer than the vocabulary. EMA marketing authorisations, MHRA licences, Health Canada DINs, TGA ARTG entries, PMDA approvals, NMPA registrations and CDSCO clearances are different stamps for a shared idea: a named manufacturer, a reviewed dossier, and postmarket duties. Pharmacy compounding and hospital preparation exist in every system; the US 503A/503B vocabulary does not. The careful comparative claim is modest: other jurisdictions also distinguish authorised industrial manufacture from pharmacy preparation and from illicit trade — they simply draw the lines with different statutes.^{2, 10}

Section 09aIncentives that keep industrial workshops honest — or not

Approved manufacturers live under inspection, complaint handling, recall power and product-liability exposure that make cutting corners expensive. CDMOs live under customer audits and the threat of lost long-term contracts. Those incentives are imperfect — Form 483s and consent decrees exist because failures happen — but they are thicker than the incentives facing an online seller who can rename a storefront overnight. Specialty pharmacies and GPOs allocate scarce approved product; their allocation choices during shortage became part of the political story of incretin access. None of this requires believing that every licence holder is virtuous. It requires noticing that the feedback loops differ by workshop.^{6, 13}

Biotech sponsors without factories of their own intensify CDMO dependence. A virtual company can own a BLA and still never touch a reactor. That arrangement is normal. It becomes fragile when every sponsor queues for the same peptide trains and lyophilisers. Trade and market-research reporting in 2025–2026 repeatedly named the same capacity story: named peptide CDMOs (Bachem, Lonza, PolyPeptide and peers) announcing multi-hundred-million-dollar solid-phase and sterile fill-finish expansions; commercial reactors described as booked years ahead; GLP-1 demand cited as the demand shock. Those figures are directional commercial context, not audited census data and not legal authority. They are weighed here only as evidence that industrial peptide supply is a bottleneck industry, not a commodity print shop — and that when licensed capacity lags demand, compounding and gray channels fill the narrative space whether or not they fill the quality gap.

The industrial map therefore has two clocks. The regulatory clock asks whether a finished product is authorised. The capacity clock asks whether anyone with a qualified plant can make enough of it. Originators expanded supply; CDMOs expanded trains; shortages still occurred. Understanding who made a vial requires noticing both clocks. A compounded or falsified vial can appear precisely when the capacity clock is late, even if the regulatory clock still says “approved product exists.”

Compounding exists because medicine is sometimes too irregular for a catalogue. A patient may need a liquid instead of a solid, a different strength, or a formulation without an allergen present in the approved product. Hospitals may need a presentation that manufacturers do not stock. During a declared shortage, compounders may lawfully produce copies that would otherwise be restricted, provided other statutory conditions are met. Those are real public benefits. They are also the rhetorical cover under which high-demand incretin analogues became a cash-pay industry of medspas, telehealth funnels and vitamin-fortified vials.^{3, 7}

The United States statute draws two workshops. Under section 503A, a licensed pharmacist or physician compounds for an identified patient pursuant to a valid prescription, under primary state board oversight, with limits on compounding drugs that are essentially copies of commercially available products except in defined circumstances such as shortage. Under section 503B, an outsourcing facility registers with FDA, accepts CGMP, may compound sterile drugs in batches without patient-specific prescriptions, must report adverse events and provide FDA with product lists (typically on initial registration and in June and December), and may use bulk drug substances only when the substance is on the 503B Bulks List or the drug compounded from the bulk is on the shortage list at relevant times. FDA’s registration Q&A adds operational texture: electronic registration unless waived; annual establishment fee; confirmation of registration after timely payment; risk-based inspection scheduling, with newly registered facilities that have not been inspected expected, in FDA’s general expectation language, to be inspected within about two months. Registration is not product approval. CGMP is not an NDA.

After shortage listings for major incretins resolved, FDA’s public clarifications returned attention to ordinary 503A and 503B conditions. Under 503A, compounding still requires an individual-patient prescription, and regular or inordinate compounding of essentially copies remains restricted unless a documented, significant clinical difference for that patient justifies the change. Agency examples have included combination products: a vial that pairs semaglutide API with vitamin B12 (cyanocobalamin) can still be treated as essentially a copy when strengths and route match the commercially available products within the agency’s stated similarity band. Under 503B, bulk use without shortage listing or Bulks List placement remains the hard gate. Those reminders are agency policy posture as published on FDA’s compounding pages; they are not practice manuals and they are not advice to any compounder.

Section 11Benefits, weighed without romance

Individualised dosing forms, paediatric and geriatric adaptations, removal of problematic excipients, and continuity of care when a licensed presentation vanishes are the classical case for compounding. Hospital and health-system pharmacies use 503B partners for office stock that would be impractical to compound patient-by-patient. In low-resource settings, peptide hormone access problems — insulin above all — show what happens when industrial supply, price and distribution fail; compounding is not the global answer to that failure, but shortage-driven pharmacy production is one local response among many.^{2, 10, 13}

None of those benefits requires pretending a compounded vial is a generic drug. Generic drugs demonstrate bioequivalence under an abbreviated pathway. Compounded drugs do not. Calling a compounded semaglutide preparation “generic” is a marketing falsehood that regulators have flagged in warning letters and that observational website surveys have documented in the marketplace.⁷

Section 12Risks, weighed without panic

The costs are equally concrete. Premarket review of safety and efficacy is absent. Potency can vary. Sterility and endotoxin control depend on the facility’s actual practice, not its website. Aggregation and impurity profiles can diverge from the approved product. Pharmacovigilance is thinner: many 503A operations do not feed adverse-event systems the way licence holders do. Inspection intensity varies by state and by whether a facility registered as 503B. Economic incentives favour copying high-list-price products and advertising them beside spa services. Intellectual-property conflict and unfair-competition claims follow. Patient confusion is not a side effect; it is often the business model.^{7, 14, 17}

Historical memory matters here. NECC was not a peptide story, but it was a sterile-injectable compounding story, and peptide injectables inherit the same physics of contamination. Modern GLP-1 compounding controversies include salt forms (semaglutide sodium or acetate) that FDA has stated are different active ingredients from the approved base, combination products with substances FDA has flagged as unsafe for compounding (including BPC-157 in at least one Colorado advertisement), oral or troche forms without approved weight-loss counterparts, and dosing-error patterns linked to multi-dose vials rather than branded pens.⁷

Section 13The economics of high-demand peptides

List prices in the range of roughly one thousand dollars a month, patchy insurance coverage for obesity indications, Medicare coverage limits for weight-loss use, prior authorisation delays and celebrity-driven demand created a shortage and a substitute market at the same time.^{7, 14} A Colorado cross-sectional study conducted in March–April 2024 identified 93 business websites advertising compounded GLP-1 products for weight loss, mapping to 188 physical locations: medical and health spas, weight-loss clinics, wellness and anti-ageing practices, mobile/telehealth services and physician groups. Nearly all advertised semaglutide; many advertised tirzepatide; some referred to FDA approval in product descriptions; a few called the products “generic.” One advertised retatrutide, which lacked any approved commercial presentation for weight loss at the time of the survey; one advertised a combination with BPC-157.⁷

Telehealth and virtual protocols intensify the pattern. Observational programmes describing remote titration and adherence support for tirzepatide illustrate how clinical operations can be organised outside traditional office-based specialty care; they are evidence of a business and care-delivery model, not endorsements of a dose schedule in this monograph.⁸ Private-equity ownership of compounding pharmacies, white-label arrangements between clinics and pharmacies, and referral relationships create vertical integration that can align incentives toward volume. Shortage allocation by originators, rebate structures and formulary placement shape the approved side; cash-pay menus shape the compounded side. When the shortage list clears, the cash-pay menu does not automatically close — it looks for a remaining lawful toehold (documented clinical difference from the approved product) or drifts toward noncompliance.

Section 14When compounding competes rather than supplements

Compounding supplements the approved market when it serves a patient who cannot use the licensed presentation. It competes when it becomes a parallel mass channel for the same clinical desire the approved product already addresses, priced for people locked out by coverage or queue. FDA’s May 2026 proposal (91 FR 23431) to keep semaglutide, tirzepatide and liraglutide off the 503B Bulks List is an attempt to close large-scale outsourcing of those molecules even if future shortage listings reappear — a notice still awaiting final determination as of 5 August 2026 after the comment period closed 30 July 2026 (91 FR 38719). Originator citizen petitions, trade-association lawsuits (including Outsourcing Facilities Association litigation over shortage timing) and warning letters to telehealth advertisers are the adversarial legal layer around that policy. Secondary reporting described large waves of FDA warning letters to online and telehealth sellers of compounded GLP-1 products in September 2025 and further telehealth marketing letters in early 2026; each letter is a fact pattern of its own and should be read in full. This monograph does not adjudicate those cases; it notes that the dispute is live and that advertising enforcement is part of the weather around the workshops.

Investigational and unapproved peptides complicate the picture further. Clinical-practice statements on anti-obesity pharmacotherapy distinguish approved agents from investigational ones; marketplace advertising sometimes does not.^{1, 3} Retatrutide appearing on a compounding menu before approval is not a shortage bridge. It is a different legal animal entirely.

Section 14aQuality comparison in compounding practice

A fair comparison does not pretend that every 503A pharmacy is NECC, or that every 503B facility is a brand factory. It asks which controls are required, which are customary, and which are optional marketing language. Supplier qualification, incoming identity testing, environmental monitoring, aseptic technique, sterility and endotoxin testing, potency assay, beyond-use dating, complaint handling and adverse-event reporting are the practical checklist. Approved manufacturers must validate methods and run formal stability programmes; 503B facilities inherit CGMP expectations tailored by guidance; 503A pharmacies inherit USP chapters as adopted by states and whatever their board actually inspects. The gap is largest for sterile injectables — exactly the dosage form that dominates peptide commerce.^{5, 7}

Bulk-substance sourcing is the quiet hinge. A compounder that buys API from an FDA-registered establishment with a valid CoA is not in the same risk band as a compounder that accepts a research-chemical drum with a private-label PDF. FDA has separately reminded the field that food-grade or unsuitable grades of ingredients are not automatically appropriate for sterile compounding — a lesson taught in other molecule classes and applicable whenever grade and route are mismatched. Salt forms of semaglutide were a peptide-specific version of the same problem: chemical difference dressed as convenience.

The shortage bridge and the bulks gate must be kept conceptually separate. Shortage listing can temporarily loosen “essentially a copy” limits for compounders that otherwise meet statutory conditions. The 503B Bulks List is a different instrument: it asks whether there is a clinical need for outsourcing facilities to compound from a nominated bulk substance even when the approved product is commercially available. FDA’s May 2026 proposal addresses the second instrument for three named GLP-1 agonists. Commentators who collapse “shortage ended” into “bulks excluded” into “all compounding illegal forever” are compressing three distinct legal questions into a slogan. Commentators who treat every compounded vial as still authorised because “patients still want it” are compressing a clinical desire into a licence. This monograph refuses both compressions.

Dosing-error reports associated with multi-dose compounded injectable semaglutide — including hospitalisations described in secondary summaries of FDA communications — illustrate a presentation risk that branded pens were engineered to reduce. Those reports are safety signals about workshop design (vial-plus-syringe versus engineered device), not instructions for any administration technique in this document. They belong in the risk column beside sterility history, salt-form disputes and combination products.

Legitimate laboratory supply is real. Analytical reference standards, preclinical research materials and labelled reagents keep science moving. The problem is leakage: the same packaging language migrates into direct-to-consumer storefronts that sell injectable peptides with human-use innuendo, dosing blogs and “not for human consumption” footers that function as winks. A disclaimer is not a quality system. A CoA is not a clinical release. Implied human-use marketing can convert an RUO posture into an unapproved new drug problem regardless of the footer font.^{4, 12}

Illegitimate internet pharmacies selling insulin and other peptides at implausible prices have been documented as a consumer-safety problem distinct from licensed specialty pharmacy.¹² Self-administration of illegal or falsified medicines procured outside approved channels appears in case literature and enforcement narratives; those reports are signals of harm pathways, not recipes.⁴

Section 16Gray markets and counterfeits

Falsified medicines are not a metaphor. On 19 June 2024 the World Health Organization issued Medical Product Alert N°2/2024 for falsified Ozempic (semaglutide) identified in the WHO Regions of the Americas and Europe. The alert describes three falsified batches detected in Brazil (October 2023), the United Kingdom (October 2023) and the United States (December 2023), and states that the products were supplied in the regulated supply chain. The genuine manufacturer confirmed falsification: one batch number was not recognised; one batch/serial combination did not match manufacturing records; one used a genuine batch number on a falsified product. WHO warned that use may yield ineffective treatment, contamination, substituted ingredients, or other serious harms intensified by subcutaneous injection. That alert is an international public-health instrument, not a national marketing authorisation — and not an invitation for any reader of this monograph to self-administer or source product outside licensed channels.

European pharmacovigilance analysis of EudraVigilance individual case safety reports coded with counterfeit-related MedDRA terms identified 234 suspected counterfeit semaglutide cases among tens of thousands of semaglutide reports from 2018 through 2025, with a higher reporting odds for hypoglycaemia, malaise, drug ineffective and product use in unapproved indication compared with non-counterfeit-coded reports. Those codes reflect reporter suspicion; they are not laboratory confirmation of every vial.¹⁸

The risk chain is familiar: unmet demand and high prices attract illicit manufacture; false certificates and look-alike packaging lower buyer scepticism; social media and search advertising widen distribution; patients and non-patients inject outside supervised care; spontaneous reporting systems see fragments of the harm. Originators and regulators publish authentication guidance; criminals publish fake authentication sites. DSCSA was built to harden the licensed chain. It cannot police every parcel.

Section 17Inspection, enforcement and industry relationships

Enforcement is a ladder, not a light switch. Surveillance and sampling lead to inspections; Form 483 observations may lead to warning letters; civil seizure and injunction follow persistent or dangerous noncompliance; criminal prosecution remains available for fraud and adulteration. State boards act on pharmacy licences in parallel. Advertising cases may implicate FDA drug-ad jurisdiction, FTC consumer-protection theories, or both — a boundary commentators argue is poorly matched to medspa and telehealth entities that are neither classic manufacturers nor classic pharmacies.⁷ In the GLP-1 years the advertising rung was especially active: FDA warning letters to telehealth and online sellers of compounded semaglutide and tirzepatide repeatedly objected to claims that implied FDA approval, omitted risk information, or blurred compounded preparations with approved branded products. Secondary tallies described multi-dozen letter waves in late 2025 and further telehealth-focused letters in early 2026. Those waves are weather reports, not a complete census and not a substitute for reading any letter that names a specific firm.

Industry relationships knit the map together. Sponsors and CDMOs share quality agreements and capacity reservations. Compounders buy API from registered bulk manufacturers — or from less transparent brokers. Clinics refer to preferred pharmacies; some share ownership. Telehealth platforms route prescriptions into fulfilment networks. Insurers negotiate rebates with approved-product manufacturers while cash-pay clinics price against those list prices. Testing laboratories serve both compliant sponsors and online sellers. Regulators and state boards sometimes conflict on tempo and priority. None of these relationships is inherently corrupt; all of them can be.

Section 18Case studies as systems lessons

Legitimate customisation. A sterile compound prepared for a documented excipient allergy, under a patient-specific prescription, is the textbook 503A use case. It is also, in the current market, the least visible case.

Shortage bridge. During FDA shortage listings for incretin products, compounders scaled copy production that many patients experienced as access. When listings resolved in late 2024 and early 2025, the legal bridge narrowed faster than demand.^{7, 13}

NECC 2012. Contaminated sterile injectables from a compounding pharmacy operating like a manufacturer produced a national infectious disaster and the DQSA settlement between federal and state authority.

High-demand peptide dispute. Semaglutide and tirzepatide compounding became a national political economy: originator petitions, Outsourcing Facilities Association litigation over shortage timing, warning-letter waves to telehealth advertisers, and the May 2026 503B Bulks List proposal (91 FR 23431) — still not final as of 5 August 2026 after the July comment close.

503B model. Outsourcing facilities supply hospitals with batch sterile products under CGMP without patient-specific prescriptions — a designed middle path that still forbids unconstrained bulks compounding of substances lacking clinical need.

RUO leakage. Research sellers and “peptide boutiques” market injectable sequences with dual messaging; enforcement treats implied human-use commerce as an unapproved-drug problem.¹²

Counterfeit chain. WHO Alert N°2/2024 on falsified Ozempic batches in Brazil, the UK and the USA (including regulated-chain detections), with EV suspicion-coded ADRs showing distinct reporting patterns.¹⁸

Pharma response. Analytical publications on follow-on impurity profiles, citizen petitions, and supply expansion are industrial replies to parallel markets.¹⁷

State–federal tension. Boards of pharmacy, medical spa regulators and FDA advertising jurisdiction do not move in lockstep; Colorado’s DTC survey is a state-level window on a national pattern.⁷

Telehealth verticals. Remote prescribing plus compounding fulfilment creates speed and scale; it also creates advertising and quality blind spots.^{7, 8}

Section 19What a careful reader should ask

Who manufactured this finished product, and under which authorisation? Is this an approved medicine, a compounded preparation, an investigational supply, a research material, or something that refuses to say? If compounded, was there a patient-specific prescription (503A) or a registered outsourcing facility (503B)? If shortage was the justification, is the drug still on the list? If a CoA is offered, who performed the tests, on which lot, with which validated methods? If the price seems impossible, why? If the website says “FDA” in the same breath as “compounded,” what exact claim is being made? If the product is RUO, why is it being discussed as if it were clinical care?

Add the dated questions that 2024–2026 forced into the open. If shortage was the justification yesterday, is the drug still on FDA’s shortages list today? If a 503B facility is using a bulk substance, is that substance on the 503B Bulks List — and has any proposed exclusion for that substance been finalised, or is it still a Federal Register proposal? If a website cites “WHO” or “FDA,” is it citing an approval, an alert, a warning letter, or a blog post about one? If a pen looks like Ozempic, have lot and serial numbers been checked against manufacturer and regulator guidance after WHO Alert N°2/2024? If a telehealth funnel priced a vial far below list, which workshop fulfilled it, and under which statute?

Those questions will not make the ecosystem tidy. They will keep a reader from confusing a sequence string with a medicine. Peptide therapeutics are one of the great pharmaceutical successes of the century; the workshops that make and fake them are now part of that story. Understanding the workshops is not cynicism. It is literacy.^{7, 17, 18}

Section 19aWhat this monograph deliberately does not do

It does not recommend any human dose, route, cycle or unsupervised administration. It does not provide a compliance checklist that any pharmacy, clinic or CDMO could treat as counsel. It does not declare the May 2026 503B Bulks proposal a final ban. It does not treat every compounded preparation as fraud, or every approved product as flawless. It does not convert trade-press CDMO capacity numbers into audited market facts. It does not treat counterfeit-coded pharmacovigilance rows as laboratory-confirmed vials. Those refusals are part of the method. The workshop map is useful only when it stays a map.

503A / 503B. United States FD&C Act compounding pathways: traditional patient-specific compounding (503A) and outsourcing facilities (503B).

API. Active pharmaceutical ingredient — the drug substance before finished dosage-form manufacture.

BLA / NDA. Biologics License Application / New Drug Application (US).

CDMO / CMO. Contract development and manufacturing organisation / contract manufacturing organisation.

cGMP / CGMP. Current good manufacturing practice.

CoA. Certificate of analysis — an analytical snapshot, not a full quality system or clinical approval.

DSCSA. Drug Supply Chain Security Act (US traceability framework for the licensed chain).

DQSA. Drug Quality and Security Act (2013), creating modern federal compounding categories after NECC.

Essentially a copy. US compounding concept limiting routine compounding of drugs that duplicate commercially available products.

Fill-finish. Sterile filling of drug product into its final container-closure system.

NECC. New England Compounding Center — source of the 2012 fungal meningitis outbreak that precipitated DQSA.

RUO. Research use only — a designation/labelling posture, not proof of human safety or efficacy.

SPPS. Solid-phase peptide synthesis.

Shortage list. FDA-maintained list whose status can change compounding conditions for copies of approved drugs.

503B Bulks List. FDA list of bulk drug substances for which there is a clinical need for outsourcing-facility compounding; nomination and listing are distinct from shortage listing.

WHO medical product alert. International notice of substandard or falsified medical products (e.g. Alert N°2/2024 on falsified Ozempic).

Section 21Abbreviations

ANDA · ADR · ARTG · BPCIA · CDSCO · CFR · CMC · DIN · EMA · EV (EudraVigilance) · FAERS · FD&C · FTC · GLP-1 · IND · MAA · MHRA · NMPA · PHS · PMDA · PV · REMS · ROR · TGA · USP · WHO.

Section 22Producer-category comparison (abridged)

Expanded matrix: notes/QUALITY_SYSTEM_MATRIX.md and notes/PRODUCER_TAXONOMY.md.

Section 23Jurisdiction table (selected)

Section 24Dated regulatory appendix (abridged)

Primary FDA, Federal Register and WHO pages were re-fetched on 5 August 2026 via the shared research stack at C:\Apps\_env (Camoufox; discovery via Tavily/Exa; Europe PMC for literature). Fuller tables: notes/DATED_REGULATORY_APPENDIX.md and notes/API_RESEARCH_HARVEST.md.

Section 25Inspection and enforcement appendix (summary)

Typical US ladder: surveillance and sampling → inspection / Form 483 → warning letter → civil seizure or injunction → criminal referral. 503B facilities face risk-based FDA inspection after registration and annual fee payment; newly registered facilities that have not been inspected are, in FDA’s general expectation language, targeted early. 503A pharmacies face primarily state board oversight with federal backstop for FD&C violations. Advertising cases may implicate FDA and/or FTC theories. Warning letters to telehealth and compounding advertisers of GLP-1 products are part of the 2024–2026 public record, including reported multi-letter waves in late 2025 and early 2026; individual letters should be read in full before operational use. Details: notes/CASE_STUDY_MEMO.md.

Section 26Unresolved legal questions

• Final FDA determination on excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List (proposal pending as of 5 Aug 2026).
• Scope of remaining lawful 503A compounding of GLP-1 agonists after shortage resolution when a documented clinical difference from the approved product is claimed.
• State-by-state telehealth prescribing and medical-spa oversight variation.
• How FDA/FTC advertising jurisdiction applies to vertically integrated clinic–pharmacy platforms.
• True incidence of falsified peptide exposures — unknown; PV counterfeit codes are not denominators.¹⁸
• Cross-border personal importation fact patterns — case-specific.

See notes/UNRESOLVED_LEGAL_QUESTIONS.md.

Section 27Contradictory-evidence register

• Shortage timing vs compounding legality. Public chronologies, litigation stays and enforcement discretion windows do not always align; secondary summaries disagree on exact wind-down dates. Prefer FDA primary pages for operational questions.
• Follow-on impurity → clinical harm. Analytical differences between originator and follow-on/compounded GLP-1 products are documented; clinical consequence for every product is not established.¹⁷
• Counterfeit ADR patterns. Higher ROR for selected events in counterfeit-coded EV reports is a reporting association, not proof of composition.¹⁸
• Market-size figures for peptide CDMOs. Trade estimates diverge widely; used only as directional context, not as precise facts.

See notes/CONTRADICTORY_EVIDENCE.md.

Section 28Limitations and adversarial notes

Literature skew. Open peer-reviewed literature under-represents primary compounding-law articles relative to GLP-1 clinical and pharmacovigilance papers. Structural US law is therefore carried by dated official frameworks plus a smaller set of marketplace studies (notably the Colorado DTC survey). That limitation is disclosed, not papered over.

Channel reporting. Secondary vendor and composition observations may inform channel context; they are not legal authority.

Not legal advice. Operational compliance requires current official text and qualified counsel in the relevant jurisdiction.

No human-use recommendations. Access, shortage and telehealth observations are descriptive.

Section 29References

Entries are numbered and sorted by first-author surname. Every bibliographic entry was resolved from the source record’s own metadata — never from recall. In-text citations are the superscript numbers throughout the document. Official statutes, Federal Register notices and FDA administrative listings cited narratively above are jurisdiction-dated in the regulatory appendix and are not duplicated as PMC records.